Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue

This article was originally published in The Pink Sheet Daily

Executive Summary

As it tries to build market share for Recothrom, ZymoGenetics files Citizen's Petition asking FDA to remove its top competitor from the market.

You may also be interested in...

FDA Challenges ZymoGenetics' Safety Claims

Agency takes issue with part of the better-than-bovine thrombin boast.

ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks

Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.

ZymoGenetics Allies With Bayer To Blitz U.S. Hospital Market With rhThrombin

Bayer receives ex-U.S. rights to develop and market the recombinant thrombin therapy.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts